COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal (remestemcel-L) ...
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the expansion of its intellectual property protection around Prochymal® (remestemcel-L). The United States ...
JDRF Partners with Osiris on a Phase II Trial to Evaluate an Immunomodulatory Cell Therapy Product For Type 1 Diabetes New York, NY – October 25, 2007 – The Juvenile Diabetes Research Foundation ...
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. On Sept. 24, 2023, NASA's OSIRIS-REx mission made U.S. history by returning samples of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results